MS & Immune Disorders

Filter Your Results




Social Networks May Be a Modifiable Risk Factor for MS Progression

Monday, March 04, 2019—Using social network surveys to identify patients with stronger vs weaker social networks (SNs), researchers found that persons with multiple sclerosis (MS) who had significan…

Positive Long-Term Efficacy and Safety of Teriflunomide

Monday, March 04, 2019—Annualized relapse rates (ARR) were significantly lowered for patients treated with 14 mg teriflunomide (Aubagio; Sanofi, Bridgewater, NJ) compared with those treated with pla…

Positive Results for Ublituximab in Phase 2 Clinical Trial

Saturday, March 02, 2019—Patients with relapsing-remitting multiple sclerosis (RRMS) who were treated with ublituximab (TG Therapeutics, New York, NY) (n = 46) had rapid depletion of B cells, reduced …

Early Treatment of Clinically Isolated Syndrome With Interferon ß-1b Shows Benefit Over a 15-Year Period

Saturday, March 02, 2019—Patients with clinically isolated syndrome (CIS) who were treated with interferon ß-1b (IFN) show long term benefits of early treatment (initiation within 2 years of dia…

Partnership Between Community and Academic Healthcare Can Improve Standardization of Imaging Protocols for Multiple Sclerosis

Saturday, March 02, 2019—Guidelines exist for standardized MRI for monitoring disease activity in patients with multiple sclerosis (MS) and enhance quality of care for patients as well as creating the…

Rates of Initiating Disease-Modifying Treatment for Multiple Sclerosis Remain Low

Friday, March 01, 2019—Research suggests that as many as 43% of patients with multiple sclerosis (MS) do not take a disease-modifying treatment (DMT) for the first 2 years of their diagnosis or long…

Comparative Protein Expression Analysis for Precision Diagnosis of Multiple Sclerosis

Friday, March 01, 2019—Gene coexpression with transcriptome analysis, a measure of what genes are actually expressed in an individual, has been used to distinguish patients with relapsing-remitting …

Alemtuzumab Effective for Treatment of MS Over 8 Years of Follow Up

Friday, March 01, 2019—After 8 years of treatment with alemtuzumab (Lemtrada; Sanofi, Bridgewater, NJ), patients treated with 3 or more courses of the drug had an annualized relapse rate (ARR) of 0.…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.